Posts in category: Pharmaceutical

New York, NY, June 26, 2021 –(PR.com)– The quality of active pharmaceutical ingredients (APIs) will directly affect the efficacy and safety of drugs. Alfa Chemistry has been an active player in the chemical industry and is committed to supplying what consumers exactly need. Guided by this, the company recently announces to have diversified its plentiful supply of varieties of active pharmaceutical ingredients, which could be used for pharmaceutical preparation.

API refers to the biologically active component of a drug product, either in the form of tablet or capsule, thus API molecules have many chemical functional groups. All the drugs are made up of two central components, namely, APIs and pharmaceutical excipients.

“The ever-growing demand for innovative medicines naturally leads to an increasing demand for efficient and effective management of APIs manufacturing. In such a case, our management has decided to diversify and upgrade our supply of APIs, trying to bring the best quality, high purified chemicals to our customers,” says the Marketing Chief of Alfa Chemistry.

APIs may exist in the form of liquids, powders, crystals, and based on different sources, APIs can be categorized into synthetic chemical API, biotechnology API (traditional fermentation API and modern biotech API), natural API, with each type obtained by chemical synthesis, biotechnology, or plant extraction.

As for now, Alfa Chemistry offers a variety of synthetic chemical APIs which can be used in the pharmaceutical preparation, which are listed as below:

– Donepezil
– Dexmedetomidine Hydrochloride
– Lenalidomide
– Parecoxib Sodium
– Rivaroxaban
– Tofacitinib Citrate
– Tamoxifen Citrate
– Epalrestat
– Edaravone

All APIs at Alfa Chemistry are strictly QC assessed so that high quality is guaranteed. Technique documents such as COA are also provided. In addition to APIs, Alfa Chemistry also offers pre-formulation drug discovery, formulation and process development, custom synthesis, and scale up services. Please visit the website: https://www.alfa-chemistry.com/ to learn more.

About Alfa Chemistry
Alfa Chemistry is a trust-worthy supplier of various chemicals as recognized by pharmaceutical companies, universities and research institutions. To meet the most recent market demand, the company is now expanding and optimizing its product lines. Some newly emerging or rare chemicals that can be hardly found elsewhere are now available at Alfa Chemistry as well.

by The Manufacturer

The need to rapidly scale up production, while maintaining the validated process, in the face of the COVID-19 pandemic left many pharmaceutical manufacturers questioning their increasingly offshore supply chains. But what is the answer when it comes to shoring up supply of raw materials and ensuring production requirements can be met?

Pharmaceutical manufacturing supply chains are complex and, as highlighted by the impact of the Covid-19 pandemic, also fragile.  

The global Covid-19 pandemic has wreaked havoc with pharmaceutical manufacturing supply chains since it began. At a time when supplies of Active Pharmaceutical Ingredients (APIs), intermediaries and additives needed to be as solid and reliable as ever, it was the very thing they were needed to combat, Covid-19, that was disrupting their availability.

Covid-19 triggered greater demand for drugs 

The global health emergency caused by the COVID-19 pandemic led to an unprecedented level of scientific collaboration and achievement, resulting in no fewer than 17 approved vaccines (at time of writing), with a further 117 candidates currently undergoing clinical trials. 

However, while demand for COVID vaccines is sky-high — 14bn doses are estimated to be needed by the end of 2021, according to Gavi, the Vaccine Alliance — the process of scaling up manufacturing of these vaccines from zero to billions has not been without its challenges. 

Having had to discard up to 15m vaccine doses in March when materials for its vaccine were mixed up with AstraZeneca’s, Johnson & Johnson’s COVID vaccine experienced another setback recently as lingering production holdups led to zero doses being shipped one week in May. 

Nevertheless, Gavi says the current capacity for COVID-19 vaccines alone is three times the annual doses produced each year for all other vaccines combined. This highlights just how remarkable the COVID-19 vaccine production drive has been. But supply issues have resulted in some countries imposing export bans for vaccines or for some of the components used to manufacture them. These bans, plus a global shipping crisis and rising API costs, caused a major bottleneck, as big an issue in supply as insufficient manufacturing capacity.